Early measurement of urinary N-acetyl-β-glucosaminidase helps predict severe hyponatremia associated with cisplatin-containing chemotherapy

Journal of Infection and Chemotherapy

Volumn 21, Issue 7, 2015, Pages 502-506

  Arakawa, Yasuhiro ^a   Tamura, Miho ^a   Sakuyama, Toshikazu ^a   Aiba, Keisuke ^a   Eto, Seiichiro ^a   Yuda, Masami ^a   Tanaka, Yujiro ^a   Matsumoto, Akira ^a   Nishikawa, Katsunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin containing chemotherapy; Hyponatremia; Urinary N Acetyl glucosaminidase

Indexed keywords

CISPLATIN; CREATININE; DOCETAXEL; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; N ACETYL BETA GLUCOSAMINIDASE; SODIUM; ACETYLGLUCOSAMINIDASE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; CREATININE BLOOD LEVEL; DIARRHEA; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPONATREMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUTROPENIA; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; STOMACH CANCER; URINE LEVEL; CHEMICALLY INDUCED; MIDDLE AGED; NEOPLASMS; URINE;

ACETYLGLUCOSAMINIDASE; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; CISPLATIN; FEMALE; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 84952629333     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2015.03.008     Document Type: Article

References (27)

1. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small cell lung Cancer collaborative Group. BMJ 1995, 311:899-909.
2. Go R.S., Adjei A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999, 17:409-422.
3. Covens A., Carey M., Bryson P., Verma S., Fung Kee Fung M., Johnston M. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002, 85:71-80. 10.1006/gyno.2001.6552.
4. Miller R.P., Tadagavadi R.K., Ramesh G., Reeves W.B. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2010, 2:2490-2518. 10.3390/toxins2112490.
5. Tiseo M., Martelli O., Mancuso A., Sormani M. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 2007, 138-144.
6. Bodnar L., Wcislo G., Gasowska-Bodnar A., Synowiec A., Szarlej-Wcisło K., Szczylik C. Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 2008, 44:2608-2614. 10.1016/j.ejca.2008.08.005.
7. Perazella M.A., Moeckel G.W. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 2010, 30:570-581. 10.1016/j.semnephrol.2010.09.005.
8. Hamdi T., Latta S., Jallad B., Kheir F., Alhosaini M.N., Patel A. Cisplatin-induced renal salt wasting syndrome. South Med J 2010, 103:793-799. 10.1097/SMJ.0b013e3181e63682.
9. Siew E., Ware L., Ikizler T. Biological markers of acute kidney injury. J Am Soc Nephrol 2011, 22:810-820. 10.1681/ASN.2010080796.
10. Westhuyzen J., Endre Z.H., Reece G., Reith D.M., Saltissi D., Morgan T.J. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transpl 2003, 18:543-551.
11. Coca S.G., Parikh C.R. Urinary biomarkers for acute kidney injury: perspectives on translation. Clin J Am Soc Nephrol 2008, 3:481-490. 10.2215/CJN.03520807.
12. Coca S.G., Yalavarthy R., Concato J., Parikh C.R. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int 2008, 73:1008-1016. 10.1038/sj.ki.5002729.
13. Wiland P., Swierkot J., Szechiński J. N-acetyl-beta-D-glucosaminidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-dose methotrexate treatment. Rheumatology 1997, 36:59-63.
14. Olsen K.M., Rudis M.I., Rebuck J.A., Hara J., Gelmont D., Mehdian R., et al. Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 2004, 32:1678-1682. 10.1097/01.CCM.0000134832.11144.CB.
15. Ren L., Ji J., Fang Y., Jiang S., Lin Y., Bo J., et al. Assessment of urinary N-acetyl-β-glucosaminidase as an early marker of contrast-induced nephropathy. J Int Med Res 2011, 39:647-653. 10.1177/147323001103900234.
16. Tamura S., Imano M., Takiuchi H., Kobayashi K., Imamoto H., Miki H., et al. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403). Anticancer Res 2012, 32:1403-1408.
17. Nakamura K., Kato K., Igaki H., Ito Y., Mizusawa J., Ando N., et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, next study). Jpn J Clin Oncol 2013, 43:752-755. 10.1093/jjco/hyt061.
18. Koizumi W., Narahara H., Hara T., Takagane A., Akiya T., Takagi M., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008, 9:215-221. 10.1016/S1470-2045(08)70035-4.
19. Kanda Y. Investigation of the freely available easy-to-use software "EZR" for medical statistics. Bone Marrow Transpl 2013, 48:452-458. 10.1038/bmt.2012.244.
20. Hanley J., McNeil B. The meaning and use of the area under a receiver operating characteristic (ROC ) curve. Radiology 1982, 143:29-36.
21. Delong E.R., Delong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
22. Dos Santos N.A.G., Carvalho Rodrigues M.A., Martins N.M., dos Santos A.C. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol 2012, 86:1233-1250. 10.1007/s00204-012-0821-7.
23. Ando N., Kato H., Igaki H., Shinoda M., Ozawa S., Shimizu H., et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 2012, 19:68-74. 10.1245/s10434-011-2049-9.
24. Sugawara M., Katada C., Katada N., Takahashi K., Higuchi K., Komori S., et al. Retrospective evaluation of adverse events of neoadjuvant or induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal squamous cell carcinoma. Esophagus 2013, 10:65-69. 10.1007/s10388-013-0365-9.
25. Hironaka S., Tsubosa Y., Mizusawa J., Kii T., Kato K., Tsushima T., et al. A phase I/II study of biweekly docetaxel (D) in combination with fixed-dose cisplatin plus fluorouracil (CF) in patients (pts) with advanced esophageal cancer (AEC) (JCOG0807). ASCO Meet Abstr 2013, 31:e15016.
26. Takimoto T., Nakabori T., Osa A., Morita S., Terada H., Oseto S., et al. Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients. Int J Clin Oncol 2012, 17:395-398. 10.1007/s10147-011-0304-5.
27. Liamis G., Milionis H., Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis 2008, 52:144-153. 10.1053/j.ajkd.2008.03.004.